Jupiter Topco LLC Invests $22.39 Million in Palisade Bio, Inc. $PALI

Key Points

• Jupiter Topco LLC acquired 10.69 million Palisade Bio shares worth approximately $22.4 million, giving it a 6.13% stake. Institutional investors and hedge funds collectively own 11.79% of the company.
• Palisade Bio shares were trading at $2.00 after a reported 5.2% decline. The company met quarterly expectations with a $0.05 per-share loss and $0.50 million in revenue.
• Analyst sentiment remains broadly positive, with a consensus “Buy” rating and an average price target of $9.00, despite mixed individual ratings. The company’s lead candidate, PDS0108, is undergoing Phase 1/2 trials for advanced solid tumors.

Jupiter Topco LLC bought a new stake in shares of Palisade Bio, Inc. (NASDAQ:PALI - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 10,689,452 shares of the company's stock, valued at approximately $22,394,000. Jupiter Topco LLC owned 6.13% of Palisade Bio as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of PALI. Perceptive Advisors LLC purchased a new position in Palisade Bio during the fourth quarter worth approximately $28,318,000. Commodore Capital LP acquired a new stake in Palisade Bio in the fourth quarter valued at approximately $26,896,000. Janus Henderson Group PLC increased its position in shares of Palisade Bio by 1.4% in the first quarter. Janus Henderson Group PLC now owns 10,689,452 shares of the company's stock valued at $18,760,000 after buying an additional 149,118 shares in the last quarter. BlackRock Inc. purchased a new stake in shares of Palisade Bio in the second quarter valued at approximately $21,813,000. Finally, Octagon Capital Advisors LP raised its stake in shares of Palisade Bio by 7.4% during the 1st quarter. Octagon Capital Advisors LP now owns 10,276,317 shares of the company's stock worth $17,984,000 after buying an additional 708,419 shares during the period. Institutional investors and hedge funds own 11.79% of the company's stock.

Palisade Bio Trading Down 5.2%

NASDAQ:PALI opened at $2.00 on Friday. Palisade Bio, Inc. has a 12 month low of $0.53 and a 12 month high of $2.86. The stock has a 50 day moving average of $2.02 and a two-hundred day moving average of $1.95. The firm has a market cap of $348.54 million, a P/E ratio of -4.17 and a beta of 1.52.

Palisade Bio (NASDAQ:PALI - Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($0.05) earnings per share for the quarter, meeting the consensus estimate of ($0.05). The firm had revenue of $0.50 million during the quarter, compared to analysts' expectations of $0.50 million. On average, research analysts forecast that Palisade Bio, Inc. will post -0.23 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on PALI shares. Wall Street Zen upgraded Palisade Bio from a "sell" rating to a "hold" rating in a research report on Saturday, July 25th. HC Wainwright reissued a "buy" rating and issued a $2.00 price target on shares of Palisade Bio in a report on Tuesday, June 30th. Oppenheimer started coverage on shares of Palisade Bio in a report on Thursday, July 23rd. They issued an "outperform" rating and a $8.00 price target for the company. Weiss Ratings cut shares of Palisade Bio from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, July 14th. Finally, LADENBURG THALM/SH SH raised shares of Palisade Bio to a "strong-buy" rating in a report on Thursday, June 25th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Palisade Bio has a consensus rating of "Buy" and an average target price of $9.00.

Insider Activity at Palisade Bio

In other news, Director Robert Jr. Baltera acquired 30,000 shares of Palisade Bio stock in a transaction that occurred on Tuesday, July 7th. The stock was purchased at an average cost of $2.03 per share, with a total value of $60,900.00. Following the purchase, the director owned 416,904 shares in the company, valued at $846,315.12. This trade represents a 7.75% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO John David Finley sold 146,798 shares of the firm's stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $2.07, for a total value of $303,871.86. Following the completion of the transaction, the chief executive officer owned 217,555 shares in the company, valued at $450,338.85. The trade was a 40.29% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders bought 125,000 shares of company stock valued at $250,100. 0.07% of the stock is owned by insiders.

Palisade Bio Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source